Qiagen expands collaboration with AstraZeneca to develop and commercialize companion diagnostics, QIAstat-Dx

Qiagen has expanded its Master Collaboration Agreement with AstraZeneca to develop companion diagnostics (CDx) for AstraZeneca’s chronic disease therapies. Qiagen will create a genotyping assay using its QIAstat-Dx platform, which allows specialty care providers to perform genotyping during routine exams. This facilitates quick decision-making regarding the suitability of AstraZeneca’s targeted treatments.

The QIAstat-Dx system, designed for laboratory use, features cost-efficient, single-use cartridges with built-in sample processing and real-time PCR for detecting multiple biomarkers within an hour. By the end of 2023, over 4,000 QIAstat-Dx instruments had been installed.

Qiagen leads in precision medicine, offering technologies like PCR, digital PCR, and next-generation sequencing. The company holds master collaboration agreements with over 30 global firms and partners with Neuron23 and Helix to develop CDx beyond oncology. Qiagen, headquartered in the Netherlands, provides comprehensive Sample to Insight solutions.